The Historical Evolution of Pharmacy Benefit Managers: From Claims Administration to Vertically Integrated Pharmaceutical Gatekeepers

Executive Summary: The PBM Evolution from Claims Administrator to Pharmaceutical Gatekeeper

Pharmacy Benefit Managers (PBMs) are third-party entities established to manage the prescription drug benefits for a diverse clientele, including health insurers, large employers, unions, and government entities.¹ PBMs originated in the 1960s as necessary administrative entities to manage the burgeoning benefit of prescription drug coverage.³ At their inception, their mandate was limited to efficiently setting reimbursement rates, processing claims, and managing payments to pharmacies, serving as fiscal intermediaries.²

The trajectory of the PBM industry has since been one of relentless functional expansion, enabled by advancements in information technology and driven by the demands of managed care organizations.⁶ PBMs have evolved from simple claims processors into increasingly complex organizations offering services such as formulary management, utilization controls (e.g., prior authorization), mail-order and specialty pharmacy services, and large-scale group purchasing.¹

The industry’s current structure is defined by intense consolidation, resulting in an effective oligopoly. Three major PBMs—CVS Caremark, Express Scripts, and OptumRx—now control nearly 80 percent of all prescriptions filled in the U.S..² This concentration is compounded by vertical integration through mergers and acquisitions that connect the PBM directly to an insurer and a pharmacy (retail, mail-order, or specialty), creating a powerful nexus across the pharmaceutical supply chain.³

The financial model has fundamentally shifted away from transparent administrative fees to one increasingly reliant on complex, opaque pricing mechanisms, primarily pharmaceutical manufacturer rebates and “spread pricing”.² This structure has led to intense regulatory and legislative scrutiny. The central controversy is the potential for structural conflicts of interest, where the PBM’s financial incentives—tied to rebate size (which correlates with list price) and internal steerage—may not align with the original purpose of lowering net drug spending for their clients and patients.¹

Chapter 1: The Genesis of the Middleman (1960s – 1970s)

1.1 The Necessity of the PBM: Integrating Prescription Coverage into Health Plans

The inception of the PBM industry occurred in the 1960s, coinciding with the era when U.S. insurers began incorporating prescription drug coverage into their standard health plans.³ This benefit expansion, while favorable to consumers, presented an immediate and daunting administrative challenge for insurers. Unlike large, infrequent medical claims, prescription drugs involved a high volume of transactions, each typically carrying a relatively small dollar value.⁶ Efficiently managing this stream of claims required specialized processes and systems that standard health insurers lacked.

PBMs emerged as third-party administrators (TPAs) contracted by payers—insurers, large employers, unions, and government entities—specifically to manage these prescription drug benefits.¹ Their initial mandate was strictly administrative and oriented toward controlling the financial administration of the benefit.⁴ The core functions of PBMs in this foundational era involved setting reimbursement rates, establishing initial pharmacy networks, processing claims, and facilitating payment to pharmacies.¹

1.2 Early Technological Adoption: The Birth of Electronic Adjudication Systems

The administrative role of PBMs quickly required technological refinement to handle scaling volumes. By the 1970s, PBMs had evolved to function as fiscal intermediaries primarily tasked with adjudicating prescription drug claims.² A significant advancement during this period was the introduction of the plastic drug benefit identification card, which standardized patient eligibility verification and streamlined the payment system.¹

PBMs rapidly became proficient in data standardization and were pioneers in the development of electronic claims processing systems.⁶ This allowed for the transition from manual, paper-based systems to early forms of electronic data exchange. By mastering this technology, PBMs achieved the necessary efficiency to manage a high volume of relatively small claims economically.⁶

1.3 Analysis of the Foundational Era (1960s–1970s)

The birth of the PBM industry was not fundamentally driven by the need to negotiate drug prices with manufacturers—a function that would emerge later—but by the imperative to manage administrative complexity. The lack of an established national healthcare information technology infrastructure capable of handling high-volume claims processing forced insurers to outsource this function, thereby creating the specialized TPA known as the PBM.

The mastery of electronic claims processing and data standardization in these early decades was critically important, establishing the framework for the PBM’s long-term power profile.⁶ If claims processing had remained decentralized and paper-based, PBMs would have likely remained simple administrative contractors. However, the drive toward electronic data aggregation created a centralized repository of comprehensive prescription data. This data asset would become the PBMs’ most valuable strategic tool, essential for implementing future functions like Utilization Management and Formulary development, profoundly changing their role from claims administrator to market influencer.⁶

Chapter 2: Expansion and Modernization: The Rise of Managed Care Tools (1980s – 1990s)

2.1 Technological Leaps: Real-Time Processing and the Consolidation of Prescription Data

The 1980s marked a transition where health plans increasingly outsourced pharmacy benefit management entirely, creating a larger, more formalized market for external PBMs.⁸ Early PBMs also began to negotiate limited drug discounts at the retail level, signaling a nascent shift beyond mere administration.⁸

The technological environment of the 1990s catalyzed a major revolution in PBM operations. This decade ushered in real-time electronic claims processing and eligibility verification at the point-of-sale, making the entire claims adjudication process paperless and significantly faster.⁶ This advance facilitated two-way communication between PBMs and pharmacies, allowing for the exchange of not only claims data but also clinical information.⁶ This electronic connectivity created an “extremely valuable tool for PBMs—a massive computer database of prescription records”.⁶ This aggregate data, pooled across numerous payers, provided PBMs with the analytical leverage needed to implement sophisticated managed care strategies.

2.2 The Introduction of Strategic Services: Mail-Order and Utilization Management

With advanced data capabilities and electronic connections, PBMs expanded rapidly into complex service offerings. The 1980s saw the introduction of the first mail-order pharmacies, enabling patients to receive 90-day supplies of maintenance medications at reduced prices.⁸ By the late 1990s, the mail service option was widely adopted, constituting nearly 10 percent of total prescriptions and over 22 percent of total budget dollars managed by PBMs, often being mandatory for retiree benefits.⁶

Simultaneously, PBMs transitioned in the 1990s toward a greater focus on patient health management, driven by the managed care environment.⁶ This included implementing Utilization Management (UM) tools, such as prior authorization and step therapy, designed to regulate drug access and cost.⁴ These tools allowed PBMs to intervene directly in the prescribing process on behalf of the payer.

2.3 Formulary Management as a Cost Control Lever

The most potent cost control mechanism developed by PBMs during this era was the creation and maintenance of formularies, which are lists of prescription drugs covered by the insurance plans they managed.³ The design of these formularies—determining which drugs were covered, at what cost-sharing tier, and whether utilization management rules applied—became a powerful lever influencing both patient access and pharmaceutical market competition.³

The efficacy of these PBM-pioneered utilization controls became evident in the broader health system. For instance, as pharmacy expenditure growth became a serious concern for state Medicaid budgets in the late 1990s and early 2000s, most states adopted similar PBM-style strategies, including Preferred Drug Lists (PDLs) and prior authorization policies, underscoring the success of these mechanisms in curbing prescription cost increases.⁹

2.4 Analysis of the Managed Care Era (1980s–1990s)

The expansion of PBM functions during this period fundamentally transformed their market role. The adoption of real-time electronic processing and the subsequent centralization of prescription data were necessary precursors to the PBM’s shift from being a passive claims processor to an active benefits manager.⁶ This data advantage enabled PBMs to assert both clinical influence through Utilization Management and significant financial leverage through formulary negotiation.

This transition into a more powerful, market-shaping role did not go unnoticed by policymakers. Even before the massive vertical mergers of the 2010s, the structural conflicts inherent in the PBM’s expanding mandate were being recognized. By the late 1990s, federal agencies such as the Federal Trade Commission (FTC), the Food and Drug Administration (FDA), and the Government Accountability Office (GAO) were already scrutinizing PBM practices related to drug switching, information disclosure, and patient access within federal employee benefit programs.⁶ This early policy attention foreshadowed the intense regulatory challenges that would define the industry in the following decades.

Chapter 3: The Economic Turning Point: The Shift to Rebate-Driven Revenue

3.1 Original Fee Structures versus Contemporary Revenue Streams

PBMs were initially designed to operate under a fee-for-service model, compensated through a set fee structure for administering benefits.² In fully transparent PBM contracts, these service fees constitute the full compensation for benefit administration.¹⁰

However, PBMs have significantly “morphed” their financial structure over time, leading to a complex and often opaque revenue model.¹ While traditional PBM contracts were primarily based on guarantees related to Average Wholesale Price (AWP) discounts, the rise of generics and specialty drugs shifted the market dynamic.¹¹ PBM revenue increasingly relies on multiple, concealed sources of profit, moving beyond simple administrative fees and centering on complex pricing arrangements.³ This functional evolution has resulted in the PBM becoming an “invisible middleman” whose true cost and value proposition are difficult for clients and regulators to assess.²

3.2 The Mechanism of Rebates: Negotiation, Retention, and the Impact on List Prices

A core function of the modern PBM is leveraging the collective purchasing power of its clients to negotiate rebates, or discounts, with drug manufacturers.³ These rebates are granted in exchange for giving the manufacturer’s product a favorable position (or access) on the PBM-managed formulary.²

This process introduces a fundamental structural conflict of interest. PBMs derive revenue by retaining a share of the negotiated rebates.³ Because rebates are typically calculated as a percentage of a drug’s List Price, the PBM has an economic incentive to favor drugs with a higher list price that yield a larger rebate, even if an alternative, lower-list-price medication might offer a lower net cost to the payer.⁷ This model prioritizes the PBM’s profit generation over pure cost minimization for the plan sponsor.

For the patient, this mechanism can directly drive up costs. Patient deductibles and co-insurance are typically calculated based on the higher list price of the drug, not the reduced net price after the rebate is applied.¹³ Analysis suggests that historically, this structure meant that higher rebates have resulted in greater out-of-pocket costs for consumers, with more than a quarter of consumer prescription costs potentially attributable to rebates alone between 1987 and 2018.¹³

3.3 Spread Pricing and Transparency Gaps

Another significant revenue source for PBMs is “spread pricing.” This practice involves the PBM charging the health plan client a higher amount for a specific drug than the amount the PBM actually reimburses the dispensing pharmacy.³ The PBM retains the difference, or the “spread”.²

Spread pricing is particularly prevalent with generic drugs because their acquisition costs are often complex and opaque, making them difficult for plan sponsors to price reasonably.¹⁰ The PBM benefits from this lack of transparency by capitalizing on the gap between the amount billed to the client and the amount paid to the pharmacy. This dynamic is typically observed in traditional PBM contracts and represents a substantial, yet often undisclosed, portion of the PBM’s gross profit.¹⁰ This systemic lack of financial visibility makes it challenging to assess the true value delivered by the PBM.¹²

3.4 Analysis of the Economic Shift

The economic turning point for the PBM industry occurred when entities realized they could leverage their role as a clinical gatekeeper (Chapter 2: Formularies and UM) to transition into a financial extractor (Chapter 3: Rebates and Spread). The industry’s strategic goal shifted from maximizing savings for their client base to maximizing revenue based on the inherent structure of pharmaceutical pricing. Consequently, the initial purpose of PBMs—to contain drug spending—is now under critical examination because the current business model incentivizes the utilization of high-cost products that yield the highest rebates.¹

This complex, opaque nature of PBM finance creates a profound policy challenge. Systemic information asymmetry is created when financial data proves insufficient to describe nearly 40 percent of PBMs’ total gross profit.¹⁰ This lack of financial visibility acts as a shield against rigorous competition and effective regulatory oversight, allowing PBMs to maintain market power without full accountability to the plan sponsors they represent.

Table 1: Shifting PBM Revenue Models: 1970s vs. Present Day

Revenue Source	Primary Role (1970s)	Dominant Role (Present Day)	Associated Controversy/Risk
Administration Fees	Primary source, set fee structure 2	Often reduced or masked by other revenue 10	Contract opacity, difficulty assessing PBM value
Manufacturer Rebates	Minimal/Non-existent	Major source of retained profit or shared savings 3	Incentivizes high list prices, rebate pass-through controversy 13
Spread Pricing	Minimal/Not systematized	Significant source, particularly for generics 2	Lack of transparency, overcharging plan sponsors
Affiliated Services	N/A	Mail-order, Specialty Pharmacy profits	Pharmacy steerage, harming independent pharmacies 3

Chapter 4: Market Concentration and the Oligopoly (2000 – Present)

4.1 Horizontal Integration: A History of Major Mergers and Acquisitions

The PBM market has been shaped by relentless consolidation. Initially, in the 1990s, there was a trend of drug manufacturers acquiring PBMs, which led to immediate antitrust concerns regarding potential conflicts of interest.¹ Federal intervention, notably through Federal Trade Commission (FTC) orders, compelled divestment, which ironically catalyzed increased consolidation within the PBM field itself.¹

This horizontal consolidation peaked in the early 2010s. A landmark event was the 2012 acquisition of rival Medco Health Solutions by Express Scripts for $29.1 billion, instantly creating “a powerhouse in managing prescription drug benefits”.¹⁴ While the FTC closed its investigation into this merger, stating that competition for accounts was intense and had driven down PBM profit margins at the time, the merger solidified the path toward an oligopoly.¹⁵

4.2 Concentration Metrics: Defining the Market Share of the “Big Three”

The market concentration that resulted from these mergers is profound. The PBM market is now dominated by three primary entities: CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (a division of UnitedHealth Group).² These “Big Three” collectively process nearly 80 percent of all prescription drugs filled in the United States, serving approximately 290 million Americans.²

The acceleration of this market power is clear in historical trends. In the 2000s, four PBMs controlled more than two-thirds of the market. By the 2010s, this concentration tightened further, with three PBMs controlling 73 percent.⁸ This indicates that market consolidation has not only occurred but has steadily increased, granting these few entities immense leverage over pricing, network formation, and formulary decisions.

4.3 The Critical Role of Medicare Part D (2006)

The implementation of the Medicare Part D prescription drug benefit in 2006 provided a significant catalyst for the growth and influence of the PBM sector.⁶ Part D is administered through private stand-alone Prescription Drug Plans (PDPs) and Medicare Advantage drug plans (MA-PDs) that contract with the federal government.¹⁶

Because the U.S. healthcare system lacks federal controls on drug pricing, PBMs provided the necessary administrative infrastructure, formulary management, and negotiation tools required for these private plans to manage the complex, high-volume benefit effectively.⁶ PBMs handle the negotiation of compensation, including rebates and concessions (known as Direct and Indirect Remuneration, or DIR) with manufacturers and pharmacies, which is factored into CMS’s final payment calculations to Part D plans.¹⁷ The sheer scale of the Part D program—covering over 54.8 million beneficiaries as of 2025—guaranteed PBMs a massive, centralized role in the federal healthcare landscape.¹⁶

4.4 Analysis of Market Concentration

The analysis of market concentration reveals a critical regulatory paradox. The FTC, in reviewing major horizontal mergers (such as Express Scripts/Medco in 2012), initially concluded that market competition was vigorous because PBMs aggressively competed for client accounts (insurers and employers).¹⁵ This narrow focus on competition between PBMs for contracts, however, overlooked the profound structural issue: the consolidation simultaneously amplified the PBMs’ monolithic leverage over other entities in the supply chain—namely, pharmaceutical manufacturers for rebates and independent pharmacies for reimbursement.⁴

This increased power over manufacturers and pharmacies established the groundwork for the most controversial vertical conflicts that would soon emerge. Furthermore, PBMs have become so pervasive and critical to the existing infrastructure, administering approximately 1.8 billion prescriptions annually—70 percent of all ambulatory care prescriptions ⁶—that they are now indispensable. Any policy reform targeting the structure of PBMs must grapple with the systemic impact of disrupting these foundational administrative and data-processing capabilities that maintain the flow of prescription benefits for millions.

Chapter 5: Vertical Integration and Emerging Conflicts of Interest

5.1 The Strategic Alignment of PBMs with Insurers and Pharmacies

The defining characteristic of the modern PBM industry is vertical integration, which involves strategic mergers and acquisitions linking PBMs with entities across the pharmaceutical supply chain.³ This integration typically binds together the PBM, a health insurer, and pharmacy services, including mail-order facilities and high-cost specialty pharmacies.¹¹

The trend toward vertical integration became highly pronounced in the 2010s.⁸ Key mergers that redefined the industry include:

1. CVS Health and Caremark (2007) followed by Aetna (2018): CVS Health initially acquired the PBM Caremark in 2007, merging retail pharmacy and PBM operations. The acquisition of the major insurer Aetna in 2018 completed a comprehensive, integrated healthcare giant.¹
2. Cigna and Express Scripts (2018): Cigna, a major insurer, acquired the PBM Express Scripts in 2018, bringing together medical and pharmacy insurance benefits under one corporate umbrella.¹
3. UnitedHealth Group and OptumRx: The existing structure of UnitedHealth Group, which includes the large insurer and the major PBM OptumRx, serves as another dominant example of vertical integration.¹

5.2 Incentives for Steerage: Maximizing Profit through Affiliated Services

Vertical integration creates powerful financial incentives for PBMs to maximize profits by steering business internally. PBMs commonly direct patients, through plan design or subtle administrative barriers, toward their own affiliated pharmacies, particularly mail-order and specialty pharmacies.²

The core financial benefit is the control over multiple profit centers. The vertically integrated entity can maximize revenue through controlled transactions: the insurer pays the PBM, which subsequently ensures the prescription is filled by the affiliated pharmacy. This process allows the corporation to maximize the retention of drug revenues and spread the profit across different segments of the organization, often at a higher effective rate than non-affiliated competitors.³ Antitrust concerns have been raised, with allegations that vertically integrated PBMs utilize their market power to ensure maximum profitability, specifically cited in cases involving high-cost insulin and specialty generics.³

5.3 Impact on Independent Pharmacies and Patient Access

The concentration of market power and the strategic financial steerage inherent in vertical integration have placed immense pressure on independent and non-affiliated pharmacies. PBMs contract with pharmacies to participate in networks, setting reimbursement terms and processing claims.³ Critics argue that PBMs often under-reimburse or apply aggressive spread pricing tactics that reduce payments to smaller, independent pharmacies.³

Independent pharmacies report significant difficulty in calculating their ultimate payment for drugs due to opaque contracts and retroactive fees.³ This resulting financial squeeze is cited as a cause for the decline and closing of independent pharmacies, leading to “pharmacy deserts” in rural and low-income areas and compromising patient access to medications and local pharmaceutical care.³

5.4 Analysis of Vertical Integration

Vertical integration fundamentally alters the PBM’s strategic objectives. When not integrated, the PBM’s survival relies on demonstrating its fiduciary value (cost savings) to its external payer clients. However, when integrated, the goal shifts to maximizing overall profit for the corporate parent, often prioritizing internal financial flow over external cost containment.¹ This means that the PBM might favor a high-cost medication that generates significant internal margin (e.g., through its specialty pharmacy) over a lower-cost alternative.

This structure significantly exacerbates information asymmetry. The vertically integrated entity possesses the ability to aggregate and utilize integrated medical and pharmacy data to inform proprietary business strategies, such as internal pricing and steerage mechanisms. This places non-affiliated insurers and competing pharmacies at a severe, actionable information disadvantage.¹

Table 2: Major Vertical Mergers and the Integration of PBMs (2007–2018)

Year	Acquiring Entity	Acquired PBM/Entity	Integration Type	Resulting Conflict of Interest
2007	CVS Health (Retail Pharmacy)	Caremark (PBM)	Pharmacy/PBM	Incentives for patient steerage to CVS retail/mail-order 1
2012	Express Scripts	Medco Health Solutions	Horizontal PBM/PBM	Significant horizontal market concentration 1
2018	Cigna (Insurer)	Express Scripts (PBM)	Insurer/PBM	Integration of medical and pharmacy benefits data 1
2018	CVS Health (PBM/Retail)	Aetna (Insurer)	PBM/Insurer	Creation of integrated health giant, cross-subsidization of revenue 1

Chapter 6: Regulatory Scrutiny, Antitrust Debates, and Policy Reform

6.1 Historical Federal Trade Commission (FTC) Engagement (2004-2019)

For nearly two decades, the FTC studied the PBM industry with a focus on competition and antitrust implications.¹⁵ Initially, the FTC and the Department of Justice’s Antitrust Division concluded in 2004 that PBMs operated in a competitive marketplace, suggesting that vigorous competition, rather than prescriptive regulation, would best achieve transparency.¹⁵

Early regulatory findings often supported PBM market activities. A 2005 FTC study suggested that PBM ownership of mail-order pharmacies did not necessarily result in higher costs for consumers.¹⁵ Furthermore, the FTC cleared major horizontal mergers, including the CVS/Caremark post-closing investigation (2012) and the Express Scripts/Medco merger (2012), based on the finding that competition for PBM accounts was “intense”.¹⁵ The DOJ similarly cleared the 2018 CVS/Aetna vertical merger, concluding that CVS was unlikely to harm rivals due to competition and commercially incentivized firewalls.¹⁵

6.2 The Policy Shift (2020-Present): Heightened Scrutiny

A dramatic policy shift commenced around 2022, fueled by growing public and political concern over escalating drug costs and reports of anti-competitive practices.¹⁵ The FTC initiated a fundamental re-evaluation, with Commissioners describing PBM practices as “cloaked in secrecy, opacity, and almost impenetrable complexity”.¹⁵

In June 2022, the FTC unanimously approved a revised 6(b) study intended to investigate PBMs’ relationships with affiliated and independent pharmacies.¹⁵ This inquiry explicitly targeted the opaque nature of their revenue operations and conflicts of interest arising from their highly integrated structure.¹⁵ FTC statements increasingly focused on the structure of the industry itself, alleging that PBM practices, including the demand for rebates, may function as kickbacks that inflate costs and limit access to affordable medicines.¹⁵ In a significant reversal of prior findings, the FTC voted in 2023 to withdraw its previous PBM advocacy, citing the “competitively troubling changes” in the market, including vertical integration and decreased transparency.¹⁵

6.3 The Direct and Indirect Remuneration (DIR) Fee Controversy

The Medicare Part D program highlighted one of the most contentious aspects of PBM finance: Direct and Indirect Remuneration (DIR) fees.¹⁷ DIR encompasses post point-of-sale compensation received by the PBM or Part D sponsor, such as manufacturer rebates and concessions paid by pharmacies, which ultimately modify the final cost of the drug for the payer.¹⁷

Historical data shows that the growth of DIR far outpaced the growth in Part D drug costs between 2010 and 2015, growing about 22 percent per year.¹⁷ Higher DIR levels were shown to moderate the financial liability of Part D plans by shifting costs into the catastrophic phase of the benefit.¹⁷ The controversy focused specifically on retroactive DIR fees, which PBMs assessed weeks or months after a prescription was filled, leaving pharmacies unable to accurately determine their final reimbursement at the point of dispensing.¹⁹

Recognizing the harm caused by this lack of transparency, the Centers for Medicare & Medicaid Services (CMS) issued a final rule eliminating the retroactive application of DIR fees, effective 2024.¹⁹ This reform mandates that these fees be reflected in the negotiated price paid at the pharmacy counter, aiming to create greater price transparency for patients and stabilize pharmacy reimbursement.

6.4 Analysis of Regulatory Dynamics

The history of PBM regulation demonstrates a critical policy adaptation lag. PBMs had successfully transformed their business model from simple claims processing (1960s) to a complex, rebate-driven vertical integration model (2010s) before regulatory frameworks fully adapted to assess the anti-competitive implications of this new structure.¹⁵ The FTC’s initial policy confidence in market competition (2004, 2012) was predicated on assessing competition for contracts, an assessment that became obsolete as the integrated structure created non-competitive internal profit capture mechanisms (steerage, rebate retention, spread pricing).¹⁵

The eventual regulatory pivot, including the launch of the 6(b) study and the 2024 DIR fee reform, represents a recognition that purely competitive market forces failed to compel the necessary fiduciary transparency from these powerful middlemen. The core issue is that the PBM structure permitted exponential growth in undisclosed financial extraction (DIR fees, retained rebates) at critical transaction points, necessitating direct governmental intervention and structural oversight to safeguard consumer and client interests.¹⁵

Chapter 7: Synthesis, Future Dynamics, and Conclusions

7.1 Synthesis: The PBM’s Indispensable Yet Controversial Role

The history of Pharmacy Benefit Managers is characterized by a dual narrative: their indispensable role in simplifying the administration of complex prescription benefits and their controversial evolution into vertically integrated, opaque financial enterprises.⁷ They arose as a unique, market-based solution to manage pharmaceutical distribution costs in the absence of federal price controls.⁷

The fundamental structural conflict is rooted in the shift of the revenue model. The current structure, dominated by three major players and reliant on manufacturer rebates and spread pricing, has inverted the PBM’s incentives. The financial goals of the vertically integrated entity—maximizing retention of rebate dollars tied to list price and steering utilization to internal pharmacies—often override the imperative to minimize net drug costs for the payer or the patient.¹

7.2 Current Market Landscape and New Entrants

The scrutiny directed toward the dominant PBM business model has stimulated innovation and the entry of disruptive new players.¹¹ These new entrants are often characterized by models prioritizing transparency and a return to fee-based compensation.

There is an accelerating shift toward “pass-through” models, where PBMs transfer nearly all rebate and spread dollars back to the plan sponsor, depending instead on clearly delineated service fees for compensation.¹⁰ This trend signals a market response to the demand for greater financial clarity. However, this transition is not without complexity; while the revenue stream shifts, the underlying drug pricing may not be inherently better than that found under traditional AWP-discount models, necessitating comprehensive, dynamic strategies from plan sponsors to ensure genuine value.¹¹

7.3 Conclusions and Strategic Recommendations

The analytical conclusion derived from the PBM industry’s history is that the accelerated growth of opaque financial mechanisms and structural conflicts ultimately mandated direct regulatory intervention. The failure of market dynamics to self-correct the issues of financial opacity (e.g., DIR fees and spread pricing) validates the necessity of recent policy actions by CMS and the heightened scrutiny by the FTC.

Based on this historical analysis, the following strategic recommendations are warranted for Plan Sponsors and Policymakers:

1. Mandatory Financial Transparency: Policymakers must focus on mandatory transparency requirements concerning spread pricing and rebate flow, particularly in the market for generic drugs, where the current lack of pricing visibility provides PBMs the greatest opportunity for undisclosed profit extraction.¹⁰
2. Strategic Contract Restructuring: Plan sponsors must move beyond traditional AWP discount guarantees in their PBM contracts. Future contracts should utilize advanced, acquisition-based pricing models that align the PBM’s compensation structure directly with the achievement of the lowest possible net cost, effectively neutralizing the rebate-driven conflict of interest.¹¹
3. Vigilance on Vertical Power: The regulatory focus must remain on the potential for anti-competitive harm caused by vertical integration, particularly the practice of patient steerage to affiliated pharmacies and the discriminatory reimbursement practices affecting independent pharmacies.³

Table 3: Key Milestones in PBM Functional Evolution

Decade	Primary Function	Key Enabling Technology/Mechanism	Market Impact
1960s–1970s	Claims Processing & Fiscal Intermediation	Early data standardization, Plastic benefit cards	Basic coverage integration, Payment facilitation for small-dollar claims 2
1980s	Network Building & Early Discounts	Real-time electronic claims, Introduction of mail-order services	Negotiation begins, Shift away from paper adjudication 8
1990s	Utilization Management (UM) & Formularies	Advanced IT/prescription databases, Managed care proliferation	Shift toward clinical and cost control intervention, Data becomes a strategic asset 4
2000s–2010s	Rebate Negotiation & Horizontal Consolidation	Medicare Part D implementation (2006), Major PBM mergers	Accelerated market concentration, Rebates become dominant revenue mechanism 3
2010s–Present	Vertical Integration & Steerage	Insurer/PBM/Pharmacy mergers (e.g., 2018), Specialty pharmacy expansion	Market oligopoly established, Structural conflicts of interest intensify 1

Works cited

1. The Morphing of Pharmacy Benefits Managers: From Claims …, accessed November 9, 2025, https://www.drugpatentwatch.com/blog/the-morphing-of-pharmacy-benefits-managers-from-claims-processing-to-vertical-integration-and-emerging-conflicts-of-interest/
2. PBM Basics – Pharmacists Society of the State of New York, accessed November 9, 2025, https://www.pssny.org/page/PBMBasics
3. What Pharmacy Benefit Managers Do, and How They Contribute to Drug Spending, accessed November 9, 2025, https://www.commonwealthfund.org/publications/explainer/2025/mar/what-pharmacy-benefit-managers-do-how-they-contribute-drug-spending
4. What are pharmacy benefit managers (PBMs) and why we need reform?, accessed November 9, 2025, https://www.ama-assn.org/health-care-advocacy/access-care/what-are-pharmacy-benefit-managers-pbms-and-why-we-need-reform
5. Insurance Topics | Pharmacy Benefit Managers – NAIC, accessed November 9, 2025, https://content.naic.org/insurance-topics/pharmacy-benefit-managers
6. The ABCs of PBMs – NCBI Bookshelf, accessed November 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559746/
7. The Evolution and Future of Pharmacy Benefits Managers, accessed November 9, 2025, https://pharmacy.wisc.edu/2024/03/13/the-evolution-and-future-of-pharmacy-benefits-managers/
8. Top 25 Moments in the History of Pharmacy Benefits Management …, accessed November 9, 2025, https://www.rxbenefits.com/blogs/25-moments-of-pharmacy-benefits-management-history/
9. Management and Delivery of the Medicaid Pharmacy Benefit – KFF, accessed November 9, 2025, https://www.kff.org/medicaid/management-and-delivery-of-the-medicaid-pharmacy-benefit/
10. Understanding the Evolving Business Models and Revenue of Pharmacy Benefit Managers – PBM Accountability Project, accessed November 9, 2025, https://www.pbmaccountability.org/_files/ugd/b11210_264612f6b98e47b3a8502054f66bb2a1.pdf?index=true
11. Understanding the debate over PBMs – Mercer, accessed November 9, 2025, https://www.mercer.com/en-us/insights/us-health-news/understanding-the-debate-over-pbms/
12. The Evolution of PBMs: A Case Study of Regulation and Litigation – Oregon Legislative Information System, accessed November 9, 2025, https://olis.oregonlegislature.gov/liz/2012R1/Downloads/CommitteeMeetingDocument/80791
13. Pharmacy Benefit Tactics Drive Up Drug Prices, Limit Access, Contribute to Health Risks, accessed November 9, 2025, https://www.pbgh.org/wp-content/uploads/2022/12/Pharmacy-Benefit-Tactics-Drive-Up-Drug-Prices-Limit-Access-Contribute-to-Health-Risks.pdf
14. Pharmacy benefit management – Wikipedia, accessed November 9, 2025, https://en.wikipedia.org/wiki/Pharmacy_benefit_management
15. PBMs and the FTC: A Timeline For almost two decades, and across …, accessed November 9, 2025, https://www.uschamber.com/assets/documents/PBMs-and-the-FTC-A-Timeline.pdf
16. A Current Snapshot of the Medicare Part D Prescription Drug Benefit – KFF, accessed November 9, 2025, https://www.kff.org/medicare/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/
17. Medicare Part D – Direct and Indirect Remuneration (DIR) – CMS, accessed November 9, 2025, https://www.cms.gov/newsroom/fact-sheets/medicare-part-d-direct-and-indirect-remuneration-dir
18. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies – Federal Trade Commission, accessed November 9, 2025, https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf
19. CMS Eliminates Retroactive DIR Fees – American Pharmacists Association, accessed November 9, 2025, https://www.pharmacist.com/Advocacy/Issues/CMS-Eliminates-Retroactive-DIR-Fees
20. Pharmacy Benefit Managers Practices Controversies What Lies Ahead, accessed November 9, 2025, https://www.commonwealthfund.org/publications/issue-briefs/2019/mar/pharmacy-benefit-managers-practices-controversies-what-lies-ahead